Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 376326, 14 pages
Review Article

Role of miRNA Let-7 and Its Major Targets in Prostate Cancer

1Small Animal Clinic, University of Veterinary Medicine Hannover, 30559 Hannover, Germany
2Institute of Biophysics, University Hannover, 30419 Hannover, Germany
3Division of Medicine, Department of Haematology/Oncology, University of Rostock, 18057 Rostock, Germany

Received 16 April 2014; Revised 11 August 2014; Accepted 18 August 2014; Published 3 September 2014

Academic Editor: Andreas Doll

Copyright © 2014 Siegfried Wagner et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer is worldwide the sixth leading cause of cancer related death in men thus early detection and successful treatment are still of major interest. The commonly performed screening of the prostate-specific antigen (PSA) is controversially discussed, as in many patients the prostate-specific antigen levels are chronically elevated in the absence of cancer. Due to the unsatisfying efficiency of available prostate cancer screening markers and the current treatment outcome of the aggressive hormone refractory prostate cancer, the evaluation of novel molecular markers and targets is considered an issue of high importance. MicroRNAs are relatively stable in body fluids orchestrating simultaneously the expression of many genes. These molecules are currently discussed to bear a greater diagnostic potential than protein-coding genes, being additionally promising therapeutic drugs and/or targets. Herein we review the potential impact of the microRNA let-7 family on prostate cancer and show how deregulation of several of its target genes could influence the cellular equilibrium in the prostate gland, promoting cancer development as they do in a variety of other human malignant neoplasias.